On 26 April 2012, orphan designation (EU/3/12/993) was granted by the European Commission to Sirius Regulatory Consulting Limited, United Kingdom, for N-hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide for the treatment of neurofibromatosis type 2.
The sponsorship was transferred to Sirius Regulatory Consulting EU Limited Ireland, in February 2019.
|Disease / condition||
Treatment of neurofibromatosis type 2
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;